Search

Displaying results 1151 - 1160 of 10000 in total
  1. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.

  2. Drug

    Helium

    go.drugbank.com/drugs/DB09155
    ApprovedInvestigationalVet approved

    It is also used as an analytical reagent in diagnostic/imaging tests to detect respiratory function of the patient. … Helium is a second most abundant chemical element in the universe with symbol He and atomic number 2.

    Mixtures: Oxygen In Helium Mix, Oxygen In Helium Mixture
  3. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma

  4. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to

  5. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.

  6. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy

  7. Drug

    Calcium acetate

    go.drugbank.com/drugs/DB00258
    Approved

    The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. … The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime.

    Mixtures: Lypholyte Multi-electrolyte Conc Inj, PERİFERAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ, 500 ML SETLİCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Capsaicin

    go.drugbank.com/drugs/DB06774
    ApprovedInvestigational

    Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements … Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations.

    Mixtures: Tianhe Gutong Tiegao (in Polyisobutylene Carrier), Transderm-IQSynonyms: (E)-8-Methyl-N-vanillyl-6-nonenamide, trans-8-Methyl-N-vanillyl-6-nonenamide
  9. Drug

    Cupric Chloride

    go.drugbank.com/drugs/DB09131
    Approved

    Cupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: Tracel Injektionslösung in einer Fertigspritze, Trace Elements Solution InjSynonyms: copper(II) chloride
  10. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).